Bullish
Eli Lilly's Inluriyo and Verzenio combo approved for advanced breast cancer treatment.
Eli Lilly's combination therapy of Inluriyo (imlunestrant) and Verzenio (abemaciclib) has been approved by the U.S. FDA for treating adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer. This approval is expected to enhance Lilly's oncology portfolio and contribute to revenue growth.
Key points
- FDA approval of Inluriyo and Verzenio combination for advanced breast cancer.
- No significant market-moving news in the past 24 hours.
Sources
AI-generated from public news sources. Not financial advice.
